# A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

> **NCT02397954** · PHASE2 · COMPLETED · sponsor: **Ophthotech Corporation** · enrollment: 4 (actual)

## Conditions studied

- Idiopathic Polypoidal Choroidal Vasculopathy

## Interventions

- **DRUG:** Avacincaptad Pegol

## Key facts

- **NCT ID:** NCT02397954
- **Lead sponsor:** Ophthotech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-12
- **Primary completion:** 2015-10-23
- **Final completion:** 2015-10-23
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02397954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02397954, "A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02397954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*